Vigamox

Plague, Sinusitis, prophylaxis of Plague + 7 more

Treatment

9 FDA approvals

7 Active Studies for Vigamox

What is Vigamox

Moxifloxacin

The Generic name of this drug

Treatment Summary

Moxifloxacin is an antibiotic manufactured by Bayer AG. It is used to treat bacterial infections orally, and is sold under the brand name Avelox (or Avalox in some countries).

Avelox

is the brand name

image of different drug pills on a surface

Vigamox Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Avelox

Moxifloxacin

1999

86

Approved as Treatment by the FDA

Moxifloxacin, also known as Avelox, is approved by the FDA for 9 uses including Sinusitis and Sinusitis .

Sinusitis

Sinusitis

Skin Infections

Plague

Community Acquired Pneumonia (CAP)

Plague

prophylaxis of Plague

Bronchitis

Communicable Diseases

Effectiveness

How Vigamox Affects Patients

Moxifloxacin is an antibiotic used to treat bacterial infections. It is effective against a variety of bacteria, including Corynebacterium, Staphylococcus, Streptococcus, Acinetobacter, Haemophilus, and Chlamydia. Moxifloxacin works by stopping the bacteria from making copies of its DNA. It binds to an enzyme called DNA gyrase that helps the bacteria replicate, and has 100 times more affinity for bacteria DNA gyrase than it does for mammalian DNA. As a broad-spectrum antibiotic, moxifloxacin is

How Vigamox works in the body

Moxifloxacin kills bacteria by blocking two enzymes, DNA gyrase and topoisomerase IV. DNA gyrase is important for making copies of bacterial DNA, while topoisomerase IV helps the bacteria divide. Blocking these enzymes prevents the bacteria from reproducing, leading to its death.

When to interrupt dosage

The prescribed measure of Vigamox is contingent upon the diagnosed condition, including ocular bacterial infections, Sinusitis and Skin Infections. The amount is contingent upon the method of delivery (e.g. Solution - Intravenous or Injection, solution - Ophthalmic), as outlined in the table below.

Condition

Dosage

Administration

Community Acquired Pneumonia (CAP)

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Postoperative Infections

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

prophylaxis of Plague

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Conjunctivitis, Bacterial

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

ocular bacterial infections

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Bronchitis

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Postoperative Inflammatory Response

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Communicable Diseases

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Plague

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Sinusitis

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Warnings

There are 20 known major drug interactions with Vigamox.

Common Vigamox Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.

Amitriptyline

Major

Moxifloxacin may increase the QTc-prolonging activities of Amitriptyline.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.

Vigamox Toxicity & Overdose Risk

An overdose of Diphenhydramine could cause decreased activity, drowsiness, tremors, seizures, vomiting, and diarrhea. The lowest amount that would be lethal in mice and rats is 100mg/kg.

image of a doctor in a lab doing drug, clinical research

Vigamox Novel Uses: Which Conditions Have a Clinical Trial Featuring Vigamox?

24 active clinical trials are presently assessing the potential of Vigamox to provide prophylaxis for Plague, Skin Infections and Bacterial Conjunctivitis.

Condition

Clinical Trials

Trial Phases

Postoperative Inflammatory Response

0 Actively Recruiting

Plague

0 Actively Recruiting

Postoperative Infections

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

ocular bacterial infections

0 Actively Recruiting

Sinusitis

2 Actively Recruiting

Not Applicable

prophylaxis of Plague

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Vigamox Reviews: What are patients saying about Vigamox?

5

Patient Review

7/19/2017

Vigamox for Pink Eye from Bacterial Infection

We've tried a lot of different treatments for pink eye in our family, and this one is by far the best. It's affordable because our insurance covers it, and it really works wonders.

5

Patient Review

1/11/2017

Vigamox for Pink Eye from Bacterial Infection

I was really shocked at how much this costs in the US. I paid less than $10 for it in Romania.

4.7

Patient Review

3/31/2016

Vigamox for Pink Eye from Bacterial Infection

The high cost of this medication is outrageous, especially when compared to other countries where it is a fraction of the price. I'm telling you, somebody is making a killing off of selling this stuff. That said, it was the only thing that helped me after trying several other options.

4.3

Patient Review

1/17/2016

Vigamox for Pink Eye from Bacterial Infection

Vigamox really helped with my pink eye, but now I have to deal with dry eyes as a result. It's been awhile since the original problem, and my eyes are still quite dry by the end of each day. In the morning, it's especially bad and feels like my eyelids are glued shut. Not ideal, but better than pink eye!

3.7

Patient Review

5/18/2016

Vigamox for Pink Eye from Bacterial Infection

The price tag on this is pretty hefty, and it's not even a very large bottle. I would recommend seeing if your doctor can give you a different option for pink eye that doesn't break the bank.

3.3

Patient Review

4/21/2016

Vigamox for Pink Eye from Bacterial Infection

The price per gallon for this treatment is absolutely absurd. An alternate pink eye treatment exists that is just as effective, costs a fraction of the price, and has none of the side effects. I would highly recommend doing your research before shelling out so much money for such a small bottle with health warnings attached.

3

Patient Review

12/1/2015

Vigamox for Ulcer of the Cornea of the Eye with Bacterial Infection

I began this medication yesterday upon being diagnosed with a corneal infection. The drops are incredibly painful, making my eye watery and red. I'm hoping that this means the medicine is working, but it's been very unpleasant so far.

2.3

Patient Review

7/6/2016

Vigamox for Pink Eye from Bacterial Infection

More expensive than the generic version I was taking previously, and not nearly as effective. There are other treatments out there that work better and faster, and don't cost as much money.

2

Patient Review

1/23/2015

Vigamox for Pink Eye from Bacterial Infection

I'm on day five of the treatment, and I haven't seen any positive results yet. The inflammation, light sensitivity, and pain are all still present. I'll be discussing other options with my doctor today.

1

Patient Review

6/25/2017

Vigamox for Pink Eye from Bacterial Infection

These drops cost me $170 with insurance and did not alleviate my symptoms whatsoever. 72 hours after starting the prescription, my eye was only getting worse; the swelling had doubled and pain was radiating from my eye to my temple. I ended up having to go back to the doctor and paying another $200 for the visit plus an additional $150 for different medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vigamox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What eye infections does Vigamox treat?

"Moxifloxacin is an antibiotic in the fluoroquinolone family that fights bacteria in the body. It come in the form of an ophthalmic solution for treating bacterial infections of the eyes. However, it will not work on viral or fungal infections of the eye."

Answered by AI

What is Vigamox used to treat?

"Vigamox is an antibiotic used to kill bacteria causing infections in the eyes."

Answered by AI

Is Vigamox eye drops a steroid?

"Are Vigamox and Tobradex effective for treating the same thing?

Yes, Vigamox and Tobradex are both effective for treating bacterial infections of the eyes."

Answered by AI

How many times a day do you use Vigamox?

"For adults, children, and newborns, the typical dosage of Vigamox is 1 drop in the affected eye(s) 3 times a day for 7 days."

Answered by AI

Clinical Trials for Vigamox

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered Vigamox clinical trials?

We made a collection of clinical trials featuring Vigamox, we think they might fit your search criteria.
Go to Trials
Image of Vancouver General Hospital in Vancouver, Canada.

In-Clinic Endoscopic Polypectomy for Nasal Polyps

18+
All Sexes
Vancouver, Canada

Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and headache, an inability to breath through the nose and complete smell loss, regularly impair one's ability to work and to enjoy and participate in daily activities. The annual cost of chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps, the most common type of chronic sinusitis, is usually treated with a combination of medications and surgery. Until now, surgical treatment has only been performed in the operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a new procedure, "in-clinic polyp removal", can provide an improvement in patient symptoms to levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in clinic polyp removal has additional advantages including a shorter procedure recovery time, a significantly lower cost to the health care system (about one-tenth the cost or $450), and a shorter wait time for treatment. With the proposed pragmatic trial, the investigators will determine whether the in clinic polyp removal procedure is as good as sinus surgery in the operating room at controlling patient symptoms of chronic sinusitis. The investigators will also determine the cost and health-benefits for a patient, the healthcare system and for society of in clinic polyp removal in comparison to sinus surgery done in a hospital operating room. The investigators will then know if this new treatment, in clinic polyp removal, can replace sinus surgery as the standard of care for these patients.

Recruiting
Has No Placebo

Vancouver General Hospital (+4 Sites)

Shaun Kilty, MD

Medtronic